Literature DB >> 29441474

Optimality, Future and Terminal Costs: Comment on "Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran".

Noga Gershon1, Yakir Berchenko2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29441474     DOI： 10.1007/s40273-018-0621-x

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  3 in total

Review 1.  Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.

Authors:  Scott D Ramsey; Richard J Willke; Henry Glick; Shelby D Reed; Federico Augustovski; Bengt Jonsson; Andrew Briggs; Sean D Sullivan
Journal:  Value Health       Date:  2015-03       Impact factor: 5.725

2.  Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al.

Authors:  Pieter van Baal; David Meltzer; Werner Brouwer
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

3.  Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy.

Authors:  Amir Ansaripour; Carin A Uyl-de Groot; W Ken Redekop
Journal:  Pharmacoeconomics       Date:  2018-01       Impact factor: 4.981
  3 in total
  1 in total

1.  Response to 'Comment on ''Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy"'.

Authors:  Amir Ansaripour; Carin A Uyl-de Groot; W Ken Redekop
Journal:  Pharmacoeconomics       Date:  2018-03       Impact factor: 4.981
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.